Northland Securities Predicts Avita Medical Q1 Earnings

Avita Medical Inc. (NASDAQ:RCEL) – Equities research analysts at Northland Securities issued their Q1 2026 earnings estimates for Avita Medical in a research note issued on Thursday, March 5th. Northland Securities analyst C. Byrnes forecasts that the company will earn ($0.35) per share for the quarter. Northland Securities currently has a “Outperform” rating and a $10.00 target price on the stock. The consensus estimate for Avita Medical’s current full-year earnings is ($0.95) per share. Northland Securities also issued estimates for Avita Medical’s Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.29) EPS, Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($1.20) EPS and FY2027 earnings at ($0.70) EPS.

Other equities analysts have also issued reports about the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Avita Medical in a report on Monday, December 29th. Lake Street Capital increased their price target on shares of Avita Medical from $3.00 to $3.50 and gave the stock a “hold” rating in a research report on Friday, January 16th. Zacks Research raised shares of Avita Medical from a “strong sell” rating to a “hold” rating in a research note on Friday, December 19th. BTIG Research upgraded Avita Medical from a “sell” rating to a “neutral” rating in a research note on Thursday, November 20th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 target price on shares of Avita Medical in a report on Tuesday, February 17th. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $6.63.

Avita Medical Stock Performance

RCEL opened at $4.75 on Monday. The stock has a fifty day moving average of $4.13 and a 200-day moving average of $4.24. Avita Medical has a fifty-two week low of $3.22 and a fifty-two week high of $10.29. The company has a market capitalization of $145.49 million, a P/E ratio of -2.71 and a beta of 1.77.

Hedge Funds Weigh In On Avita Medical

Large investors have recently bought and sold shares of the company. Farther Finance Advisors LLC acquired a new stake in Avita Medical during the 3rd quarter valued at approximately $32,000. Deutsche Bank AG grew its stake in Avita Medical by 1,351.5% in the fourth quarter. Deutsche Bank AG now owns 7,896 shares of the company’s stock valued at $27,000 after acquiring an additional 7,352 shares during the period. Russell Investments Group Ltd. grew its position in Avita Medical by 122.2% in the 4th quarter. Russell Investments Group Ltd. now owns 8,047 shares of the company’s stock valued at $28,000 after purchasing an additional 4,425 shares during the period. The Manufacturers Life Insurance Company acquired a new position in shares of Avita Medical during the second quarter valued at about $58,000. Finally, Aristides Capital LLC bought a new stake in Avita Medical during the 4th quarter worth approximately $48,000. 27.66% of the stock is currently owned by institutional investors.

About Avita Medical

Avita Medical, Inc (NASDAQ: RCEL) is a regenerative medicine company focused on the development and commercialization of cell‐based therapies for acute and chronic wounds. Its flagship technology, the ReCell® Autologous Cell Harvesting Device, enables clinicians to create a suspension of a patient’s own skin cells at the point of care. The system is designed to accelerate wound healing, minimize donor‐site requirements and reduce scarring for patients suffering from burns, traumatic wounds and a variety of surgical and reconstructive procedures.

Founded in 2009 and headquartered in Carlsbad, California, Avita Medical has secured regulatory clearances in key markets, including CE mark approval in the European Union and 510(k) clearance from the U.S.